Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from NLS Pharmaceutics ( (NLSP) ) is now available.
On July 1, 2025, NLS Pharmaceutics Ltd. announced a fifth amendment to its merger agreement with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd., extending the termination date to August 31, 2025. This extension allows the parties more time to complete the merger, demonstrating their commitment to fulfilling all regulatory requirements and aligning efforts for a successful merger completion.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a company operating in the pharmaceutical industry, focusing on the development of therapeutics for the treatment of central nervous system disorders. The company is based in Zurich, Switzerland, and is involved in a merger with Kadimastem Ltd., an Israeli company.
Average Trading Volume: 274,986
Technical Sentiment Signal: Hold
Current Market Cap: $10.04M
Find detailed analytics on NLSP stock on TipRanks’ Stock Analysis page.